Literature DB >> 10202261

Influence of age on the clinical presentation of prolactinomas in male patients.

E Delgrange1, D Maiter, J Donckier, J Tourniaire.   

Abstract

OBJECTIVE: Secreting pituitary adenomas are usually not considered a disease of older people. However, in male patients, prolactin-secreting pituitary tumours occur at a similar frequency throughout the entire life span, giving the opportunity to study in this gender the influence of age on the clinical presentation and response to treatment of these tumours.
METHODS: We conducted a retrospective study including 9 male patients aged >/=60 (range 60-73) years and 10 aged </=30 (range 17-30) years presenting with a prolactinoma in order to compare clinical presentation, results of pituitary function tests, and response to dopamine agonist therapy between older and younger patients.
RESULTS: Four of the 9 elderly as well as the 10 younger patients came to medical attention for typical features of male prolactinomas including visual field defect in 5 (2 elderly), headaches in 2 (1 elderly), impotence in 3 (1 elderly), gynaecomastia and/or galactorrhoea in 2, and arrested puberty in 2. The remaining 5 older people presented for other various reasons: symptoms related to cortisol deficiency in 2, lethargy with clinical signs of hypopituitarism in 1, spontaneous multiple vertebral fractures in 1, and incidental discovery of a pituitary mass in 1. Basal prolactin levels (3,051+/-4,151 vs. 3,365 +/- 4,949 microg/l) and mean tumour diameter (30 +/- 16 vs. 25 +/- 13 mm) were similar in old and young patients. Cortisol deficiency was significantly more frequent in the elderly (n = 6) than in the young (n = 1) patients (p 0.02, Fisher's exact test). Secondary hypothyroidism was found in 2 elderly only, but not in young patients. Sixteen patients (8 elderly) received bromocriptine therapy for at least 6 months with a good tolerance. Normalization of the prolactin levels was achieved in 6 older (75%) and 4 younger patients (50%).
CONCLUSIONS: The presentation of a prolactinoma in the elderly man is very heterogeneous and can be misleading. At the time of diagnosis, hypopituitarism is more frequent among older than younger patients despite a similar tumour size. We found dopamine agonists equally effective in the elderly.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202261     DOI: 10.1159/000022079

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  5 in total

Review 1.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

2.  Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years.

Authors:  Ilan Shimon; Dania Hirsch; Gloria Tsvetov; Eyal Robenshtok; Amit Akirov; Merav Fraenkel; Yoav Eizenberg; Dana Herzberg; Liat Barzilay-Yoseph; Anat Livner; Ilana Friedrich; Yossi Manisterski; Avraham Ishay; Uri Yoel; Hiba Masri
Journal:  Endocrine       Date:  2019-06-01       Impact factor: 3.633

Review 3.  Hyperprolactinemia in men: clinical and biochemical features and response to treatment.

Authors:  Michele De Rosa; Stefano Zarrilli; Antonella Di Sarno; Nicola Milano; Maria Gaccione; Bartolomeo Boggia; Gaetano Lombardi; Annamaria Colao
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

4.  Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.

Authors:  L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

5.  Management of macroprolactinomas.

Authors:  Amit Tirosh; Ilan Shimon
Journal:  Clin Diabetes Endocrinol       Date:  2015-07-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.